Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin,
docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with
completely resected stage IB, II, and select III NSCLC.